High-throughput Approaches in Cancer Cell Models to Enable Precision Cancer Medicine
ALL WELCOME
Mathew J. Garnett, PhD leads the Translational Cancer Genomics laboratory and Genomics of Drug Sensitivity in Cancer Project at the Wellcome Trust Sanger Institute, Cambridge UK. He aims to understand how genetic changes contribute to cancer and to identify molecular biomarkers that will improve the development of new cancer therapies using high-throughput chemical and genetic screens in cancer cell lines and organoids. Mathew is also a member of the scientific leadership team for the Centre for Therapeutic Target Validation (CTTV) which aims to use genome scale experiments and analysis to evaluate new therapeutic targets.
After obtaining a BSc in Biochemistry (Hons.) at the University of British Columbia, Canada, Mathew completed his PhD with Prof. Richard Marais at the Institute of Cancer Research (London, UK) on the characterisation of BRAF as a cancer gene. In 2005 Mathew moved to the laboratory of Prof. Ashok Venkitaraman (Cambridge, UK) for his post-doctoral research, where he discovered a new regulator of cell division. Mathew joined the Sanger Institute in 2009.
Date:
14 January 2016, 11:00 (Thursday, 0th week, Hilary 2016)
Venue:
NDM Building, Headington OX3 7FZ
Venue Details:
Basement Seminar Room
Speaker:
Dr Matthew Garnett (Sanger Institute)
Organising department:
Ludwig Institute for Cancer Research, Oxford Branch
Organisers:
Mary Muers (Oxford Ludwig Institute, NDM Experimental Medicine),
Alexandra Ward (University of Oxford, Oxford Ludwig Institute, NDM Experimental Medicine)
Organiser contact email address:
alexandra.ward@ludwig.ox.ac.uk
Host:
Dr Sebastian Nijman (Ludwig Cancer Research, Oxford)
Part of:
Ludwig Institute Seminar Series
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Mary Muers
